Our data presented in this report does not suggest that the arginine transporter CAT3 is a useful therapeutic target for controlling cancer cell access to arginine because Pten loss or an oncogenic Ptpn11 mutation-driven leukemia development is not impacted by Slc7a3 depletion. The gene discussed is PTPN11; the disease is leukemia.